Tag Ken Takeshita

Enhertu has been granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who…

Results from the VALENTINE-PTCL01 Phase 2 trial of EZHARMIA® showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma.

Results from the VALENTINE-PTCL01 phase 2 trial of Daiichi Sankyo’s EZHARMIA® (valemetostat tosilate) showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The data were presented in an oral session at the 2023…

Positive topline results from the TROPION-Breast01 Phase 3 trial.

Positive topline results from the TROPION-Breast01 Phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progressionfree survival (PFS) compared to investigator’s choice of chemotherapy in patients with inoperable or…